Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn(Consultants in Neurology), John Rose(VA Salt Lake City Healthcare System), Timothy R. Vollmer(University of Colorado Health), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Lauri Neyer(Best Biotech), Michael D. Kaufman(Carolinas Medical Center), Jacob Elkins(Biogen (United States)), Jack H. Simon(University of Colorado Health), Gilmore O’Neill(Biogen (United States)), Chungchi Wang(Best Biotech), Alice Fong(Best Biotech), James P. Sheridan(Best Biotech)
Cited by 300
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k